Mayflower Financial Advisors LLC Boosts Stock Position in Danaher Co. (NYSE:DHR)

Mayflower Financial Advisors LLC lifted its position in Danaher Co. (NYSE:DHR) by 1.7% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 2,534 shares of the conglomerate’s stock after buying an additional 43 shares during the quarter. Mayflower Financial Advisors LLC’s holdings in Danaher were worth $633,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently modified their holdings of the company. TD Asset Management Inc grew its stake in Danaher by 99.0% during the 2nd quarter. TD Asset Management Inc now owns 1,358,706 shares of the conglomerate’s stock worth $339,473,000 after purchasing an additional 675,952 shares in the last quarter. FineMark National Bank & Trust grew its stake in Danaher by 1.2% during the 2nd quarter. FineMark National Bank & Trust now owns 79,877 shares of the conglomerate’s stock worth $19,957,000 after purchasing an additional 945 shares in the last quarter. Belpointe Asset Management LLC grew its stake in Danaher by 65.5% during the 2nd quarter. Belpointe Asset Management LLC now owns 8,146 shares of the conglomerate’s stock worth $2,035,000 after purchasing an additional 3,224 shares in the last quarter. Foundations Investment Advisors LLC boosted its position in shares of Danaher by 6.1% during the 2nd quarter. Foundations Investment Advisors LLC now owns 1,555 shares of the conglomerate’s stock worth $389,000 after acquiring an additional 90 shares in the last quarter. Finally, Simon Quick Advisors LLC boosted its position in shares of Danaher by 13.3% during the 2nd quarter. Simon Quick Advisors LLC now owns 3,956 shares of the conglomerate’s stock worth $988,000 after acquiring an additional 464 shares in the last quarter. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Analyst Ratings Changes

Several research analysts have recently issued reports on the company. Robert W. Baird upped their price objective on Danaher from $271.00 to $278.00 and gave the stock an “outperform” rating in a research report on Wednesday, July 24th. Jefferies Financial Group assumed coverage on Danaher in a research report on Monday, June 3rd. They set a “buy” rating and a $295.00 price objective for the company. StockNews.com cut Danaher from a “buy” rating to a “hold” rating in a research report on Tuesday, June 25th. Bank of America upped their target price on Danaher from $270.00 to $275.00 and gave the company a “neutral” rating in a research report on Wednesday, July 24th. Finally, Stifel Nicolaus upped their target price on Danaher from $235.00 to $250.00 and gave the company a “hold” rating in a research report on Wednesday, July 24th. Seven analysts have rated the stock with a hold rating and eleven have given a buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $278.94.

Danaher Stock Performance

Shares of DHR stock opened at $264.80 on Friday. The company has a market cap of $196.13 billion, a price-to-earnings ratio of 44.88, a price-to-earnings-growth ratio of 4.43 and a beta of 0.83. The stock has a 50 day simple moving average of $260.98 and a 200-day simple moving average of $255.61. Danaher Co. has a 12-month low of $182.09 and a 12-month high of $281.70. The company has a current ratio of 1.43, a quick ratio of 1.04 and a debt-to-equity ratio of 0.33.

Danaher (NYSE:DHR) last issued its earnings results on Tuesday, July 23rd. The conglomerate reported $1.72 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.57 by $0.15. The business had revenue of $5.74 billion during the quarter, compared to the consensus estimate of $5.59 billion. Danaher had a return on equity of 11.06% and a net margin of 16.94%. The company’s revenue for the quarter was down 2.9% on a year-over-year basis. During the same period in the prior year, the business posted $2.05 EPS. On average, equities analysts forecast that Danaher Co. will post 7.59 EPS for the current year.

Insider Transactions at Danaher

In related news, SVP Georgeann Couchara sold 952 shares of the firm’s stock in a transaction that occurred on Monday, August 26th. The stock was sold at an average price of $268.37, for a total value of $255,488.24. Following the completion of the transaction, the senior vice president now directly owns 4,212 shares of the company’s stock, valued at approximately $1,130,374.44. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, CEO Rainer Blair sold 9,007 shares of the firm’s stock in a transaction that occurred on Wednesday, July 31st. The stock was sold at an average price of $280.00, for a total value of $2,521,960.00. Following the completion of the transaction, the chief executive officer now directly owns 97,983 shares of the company’s stock, valued at approximately $27,435,240. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Georgeann Couchara sold 952 shares of the stock in a transaction on Monday, August 26th. The shares were sold at an average price of $268.37, for a total value of $255,488.24. Following the sale, the senior vice president now owns 4,212 shares in the company, valued at approximately $1,130,374.44. The disclosure for this sale can be found here. In the last three months, insiders sold 39,659 shares of company stock valued at $11,042,433. Corporate insiders own 11.10% of the company’s stock.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.